Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9588600 | 0.80 | LMNA (0.32) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL1425104 | 0.79 | — | — | |
| SCHEMBL1243973 | 0.73 | LMNA (0.47) | LMNAL3MBTL1TDP1ALDH1A1KDM4E | |
| SCHEMBL27955401 | 0.73 | — | — | |
| SCHEMBL20987804 | 0.73 | LMNA (0.35) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL7114783 | 0.71 | USP2 (0.35) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL8389518 | 0.69 | — | — | |
| SCHEMBL8529658 | 0.69 | LMNA (0.50) | LMNAL3MBTL1TDP1USP2SLCO1B1 | |
| SCHEMBL1425524 | 0.69 | — | — | |
| SCHEMBL22321691 | 0.69 | LMNA (0.50) | LMNAL3MBTL1TDP1USP2SLCO1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120294924-A1 | Peptide-Lipid Conjugates And Uses Thereof | TICE THOMAS (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012148891-A1 | PEPTIDE-LIPID CONJUGATES AND USES THEREOF | EVONIK DEGUSSA CORPORATION (US) | 2012-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120294924-A1 | Peptide-Lipid Conjugates And Uses Thereof | VIP, LNPEP, NGLY1 | LMNA 2887/4885L3MBTL1 570/4885TDP1 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.